Algert Global LLC Has $8.64 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Algert Global LLC boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 10.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,206 shares of the biotechnology company’s stock after purchasing an additional 6,654 shares during the period. Algert Global LLC owned about 0.07% of Sarepta Therapeutics worth $8,643,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. lifted its stake in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares during the last quarter. CIBC Asset Management Inc raised its position in Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after purchasing an additional 86 shares during the last quarter. EP Wealth Advisors LLC boosted its stake in shares of Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 103 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock valued at $1,000,000 after purchasing an additional 120 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its holdings in shares of Sarepta Therapeutics by 3.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock worth $557,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on SRPT shares. Barclays dropped their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. UBS Group raised their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Finally, William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Two analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $114.23 on Friday. The stock has a 50-day moving average of $122.00 and a 200-day moving average of $131.56. Sarepta Therapeutics, Inc. has a one year low of $78.67 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market cap of $10.91 billion, a PE ratio of 91.38 and a beta of 0.81.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.